Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that CEO Peter Greenleaf will present at the Oppenheimer 33rd Annual Virtual Healthcare Conference from March 13-15, 2023. His presentation is scheduled for March 14, from 9:20 to 9:50 AM ET. Interested individuals can access the live audio webcast via the Investors section of the Aurinia website.

Aurinia is dedicated to addressing autoimmune, kidney, and rare diseases, having launched LUPKYNIS® (voclosporin) in January 2021 as the first FDA-approved oral treatment for lupus nephritis.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.

• Oppenheimer 33rd Annual Virtual Healthcare Conference being held March 13 – 15, 2023. Presentation time Tuesday, March 14, from 9:20 – 9:50 AM ET.

To participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by autoimmune, kidney and rare diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005026/en/

Investor/Media Contact:

Aurinia@westwicke.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When is Peter Greenleaf’s presentation at the Oppenheimer Healthcare Conference?

Peter Greenleaf's presentation is on March 14, 2023, from 9:20 to 9:50 AM ET.

How can I access the Aurinia Pharmaceuticals presentation?

You can access the presentation via the live audio webcast in the Investors section of Aurinia's website.

What is the focus of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals focuses on developing therapies for autoimmune, kidney, and rare diseases.

What product did Aurinia introduce in January 2021?

In January 2021, Aurinia introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for lupus nephritis.

What is Aurinia Pharmaceuticals' stock symbol?

The stock symbol for Aurinia Pharmaceuticals is AUPH.